remdesivir

Gilead stops Veklury study, citing enrollment challenges, changing treatment
Gilead stops Veklury study, citing enrollment challenges, changing treatment
BioPharma Dive
Gilead Sciences
COVID-19
remdesivir
Veklury
clinical trials
Flag link:
India axes exports of Gilead Sciences' remdesivir, plots boost to local production as COVID cases mount: reports
India axes exports of Gilead Sciences' remdesivir, plots boost to local production as COVID cases mount: reports
Fierce Pharma
India
drug manufacturing
Gilead Sciences
remdesivir
COVID-19
Flag link:
Pharma Gilead has sole rights to COVID-19 blockbuster Veklury, GAO concludes
Pharma Gilead has sole rights to COVID-19 blockbuster Veklury, GAO concludes
Fierce Pharma
Gilead Sciences
remdesivir
Veklury
GAO
COVID-19
Flag link:
Remdesivir, Given to Half of Hospitalized Covid Patients in U.S., Is Big Win for Gilead — Boosted by Taxpayers
Remdesivir, Given to Half of Hospitalized Covid Patients in U.S., Is Big Win for Gilead — Boosted by Taxpayers
KHN
Gilead Sciences
remdesivir
COVID-19
Flag link:
Cancer drug derived from sea squirts outperforms remdesivir in COVID-19 preclinical models
Cancer drug derived from sea squirts outperforms remdesivir in COVID-19 preclinical models
Fierce Biotech
PharmaMar
plitidepsin
Aplidin
remdesivir
COVID-19
Flag link:
Gilead says Veklury should work against COVID-19 variants
Gilead says Veklury should work against COVID-19 variants
Pharmaforum
Gilead Sciences
Veklury
remdesivir
B.1.1.7 variant
Flag link:
Gilead Updates 2020 Guidance with Post-Holiday COVID-19 Spike
Gilead Updates 2020 Guidance with Post-Holiday COVID-19 Spike
BioSpace
Gilead Sciences
COVID-19
remdesivir
Veklury
Flag link:
Could a lymphoma drug work better against COVID-19 than Gilead's remdesivir?
Could a lymphoma drug work better against COVID-19 than Gilead's remdesivir?
Fierce Biotech
China
COVID-19
Gilead Sciences
remdesivir
Folotyn
Acrotech Biopharma
Flag link:
Fierce Pharma's top 2020 marketing stories pack pandemic punch to digital, reputation and drug launches
Fierce Pharma's top 2020 marketing stories pack pandemic punch to digital, reputation and drug launches
Fierce Pharma
pharma marketing
drug pricing
COVID-19
pandemic
remdesivir
Gilead Sciences
HIV
PrEP
Pfizer
Flag link:
Where Will Gilead Sciences Be in 1 Year?
Where Will Gilead Sciences Be in 1 Year?
Motley Fool
Gilead Sciences
Veklury
remdesivir
COVID-19
Flag link:
WHO's decision to reject remdesivir based on flawed study, health experts say
WHO's decision to reject remdesivir based on flawed study, health experts say
Beckers Hospital Review
WHO
Gilead Sciences
remdesivir
COVID-19
Flag link:
Have Gilead's Gains Evaporated in the Coronavirus Treatment Race?
Have Gilead's Gains Evaporated in the Coronavirus Treatment Race?
Motley Fool
Gilead Sciences
COVID-19
remdesivir
Flag link:
Eli Lilly picks up another Covid-19 EUA as regulators wave through its Olumiant plus remdesivir combo
Eli Lilly picks up another Covid-19 EUA as regulators wave through its Olumiant plus remdesivir combo
Endpoints
Eli Lilly
FDA
COVID-19
Emergency Use Authorization
olumiant
remdesivir
Flag link:
WHO group recommends against using remdesivir to treat hospitalized Covid-19 patients
WHO group recommends against using remdesivir to treat hospitalized Covid-19 patients
Stat
WHO
Gilead Sciences
remdesivir
COVID-19
Veklury
Flag link:
After WHO trial failure, influential medical group advises against Gilead's remdesivir in COVID critical care: Reuters
After WHO trial failure, influential medical group advises against Gilead's remdesivir in COVID critical care: Reuters
Fierce Pharma
Gilead Sciences
remdesivir
Veklury
COVID-19
Flag link:
Will Gilead's Remdesivir Only Be a Short-Lived Success Story?
Will Gilead's Remdesivir Only Be a Short-Lived Success Story?
Motley Fool
Gilead Sciences
remdesivir
COVID-19
Veklury
Flag link:
Gilead should give up FDA voucher for remdesivir, patient advocates say
Gilead should give up FDA voucher for remdesivir, patient advocates say
Beckers Hospital Review
Gilead Sciences
remdesivir
FDA
Public Citizen
Flag link:
Gilead Sales Up 18% in Q3, Thanks to Coronavirus Treatment Remdesivir
Gilead Sales Up 18% in Q3, Thanks to Coronavirus Treatment Remdesivir
Motley Fool
Gilead Sciences
earnings
Veklury
remdesivir
COVID-19
Flag link:
WHO: Nations mulling Gilead's COVID drug should consider trial flop, too
WHO: Nations mulling Gilead's COVID drug should consider trial flop, too
Reuters
Gilead Sciences
remdesivir
WHO
clinical trials
COVID-19
Flag link:
Gilead's Remdesivir First Drug to Win FDA Approval for Coronavirus
Gilead's Remdesivir First Drug to Win FDA Approval for Coronavirus
Motley Fool
Gilead Sciences
remdesivir
FDA
COVID-19
Flag link:

Pages